1. Scrip
  2. >>Leadership

Pharma 'All-Stars' Talk Hot Topics At Forbes Summit

 
• By Jessica Merrill

Some of pharma's biggest names debated the pressing issues impacting industry, including pricing, image and the inter partes review system. Then, a cancer patient stood up and asked a question that reminded everyone of the issues facing patients.

Tightrope walker

Five of industry's top leaders took the stage together at the Forbes Healthcare Summit in New York Nov. 30 to discuss some of the most pressing issues facing the industry, and as usual during what is billed as "the pharma all-stars" panel, there was kinship, discord and a few fireworks.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Zepbound Grows, But CVS/Novo Nordisk Deal For Wegovy Casts Shadow

 
• By Alaric DeArment

Lilly executives told the company’s Q1 call they were not surprised at the Wegovy deal, but some analysts said it could cut into prescription growth for Zepbound.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

 
• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Could There Be A Cure For Cardiometabolic Disease? Novo Nordisk Foundation Wants To Help Academics Find Out

 
• By Andrew McConaghie

The not-for-profit’s senior vice president Martin Ridderstråle explains how it is expanding grants for basic research to improve "human and planetary" health.